Drugs / MGC028
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | US (FDA) | — | — | — | “The Company submitted an IND application for MGC028 to the U.S. Food and Drug Administration (FDA) in October.” macrogenics.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06723236 | Feb 2025 → Nov 2026 expected | cholangiocarcinoma, colorectal carcinoma, exocrine pancreatic carcinoma, lung adenocarcinoma | MacroGenics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | MacroGenics | Regulatory MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results macrogenics.com ↗
In that regard, we are pleased to have submitted the IND for MGC028, our next topoisomerase I inhibitor-based ADC, and look forward to commencing the dose escalation study in the coming months, |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | MacroGenics | MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results macrogenics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGC028 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06723236 ↗ |
| Route | Intravenous | “Dose level 1 of MGC028, IV” NCT06723236 ↗ |
| Target | ADAM9 | “MGC028 is an antibody-drug conjugate targeted against ADAM9.” NCT06723236 ↗ |